Introduction
============

Alveolar soft part sarcoma (ASPS) is a rare type of highly vascular tumor, which accounts for between 0.5 and 1.0% of all soft tissue sarcomas ([@b1-ol-0-0-5779]). It predominantly affects adolescents and young adults between 15 and 35 years of age, and most commonly occurs in the head and neck ([@b2-ol-0-0-5779],[@b3-ol-0-0-5779]). ASPS consists of numerous epithelioid tumor cells which are arranged in a pseudoalveolar growth pattern or nests ([@b4-ol-0-0-5779]). ASPS is an indolent painless disease that exhibits increased metastatic rates by the time of diagnosis ([@b5-ol-0-0-5779]). The marked fatality rate, and poor 5-year and median survival rate ([@b6-ol-0-0-5779]) observed in patients with ASPS make it a high-risk disease. The pathogenesis of ASPS remains unclear and ASPS is resistant to the standard cytotoxic chemotherapy regimens that are typically used in the treatment of soft tissue sarcomas ([@b7-ol-0-0-5779]), therefore, complete excision of the primary tumor is the therapy of choice ([@b8-ol-0-0-5779]). Radiation therapy may accompany limited surgery to provide marked palliation for patients ([@b9-ol-0-0-5779]); however, radiation therapy does not provide any survival advantage to patients ([@b8-ol-0-0-5779]). Therefore, there is no effective systemic treatment for patients with unresectable metastatic disease.

Previously, research has been conducted on molecularly targeted treatments for curing systemic cancer ([@b10-ol-0-0-5779]). ASPS is characterized by a tumor-specific translocation of der([@b17-ol-0-0-5779])t(X;17)(p11;q25) ([@b11-ol-0-0-5779]). The translocation may lead to fusion of the transcription factor 3 (*TFE3*) gene at Xp11 with the alveolar soft part sarcoma locus (*ASPL*) gene at 17q25, which codes for an ASPL-TFE3 fusion protein that appears to act as an aberrant transcription factor, inducing unregulated transcription of TFE3-regulated genes ([@b11-ol-0-0-5779]). As a transcriptional target of ASPL-TFE3, c-Met receptor (MET) may contribute to the malignant progression in ASPS ([@b12-ol-0-0-5779]). In addition, tyrosine kinase inhibitors (TKIs) may be used due to the marked levels of activated receptor tyrosine kinases (RTKs), including platelet-derived growth factor receptor (PDGFR), epidermal growth factor receptor and MET family members in ASPS ([@b13-ol-0-0-5779]). This alteration in medical management has led to the identification of novel pharmaceutical targets.

Cediranib (AZD-2171) is an orally bioavailable potent small-molecule inhibitor which consists of three vascular endothelial growth factor receptor (VEGFR) tyrosine kinases: VEGFR-1, −2 and −3 ([@b14-ol-0-0-5779]). It is able to mediate angiogenesis and lymphangiogenesis by inhibiting the development of new blood vessels, and has recently been identified to exhibit antitumor activity ([@b15-ol-0-0-5779]). Cediranib has been safely applied in clinical practice, whether as a single agent or in combination with other agents, in patients with progressed cancer ([@b16-ol-0-0-5779]--[@b18-ol-0-0-5779]). Kummar *et al* ([@b15-ol-0-0-5779]) reported that cediranib exhibited marked single-agent activity when used to treat metastatic ASPS. Therefore, in order to elucidate the underlying molecular mechanism for the treatment of ASPS with cediranib, expression profiles were evaluated utilizing a focused ASPS tissue microarray which was downloaded from the Gene Expression Omnibus (GEO) and evaluated using Gene Set Enrichment Analysis (GSEA). Using this unique bioresource, the differentially expressed genes (DEGs), signaling pathways and protein-protein interaction (PPI) networks that are involved in the development of ASPS were identified.

Materials and methods
=====================

### Microarray data

Gene expression profile GSE32569 was downloaded from the GEO database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)). A total of 6 samples that were treated with cediranib (case group) for between 3 and 5 days, and 6 samples without any treatment (control group) were included in the dataset. The dataset was based on the GeneChip^®^ Human Genome U133 Plus 2.0 Array (Affymetrix, Inc., Santa Clara, CA, USA; [www.affymetrix.com/catalog/131455/AFFY/Human+Genome+U133+Plus+2.0+Array](www.affymetrix.com/catalog/131455/AFFY/Human+Genome+U133+Plus+2.0+Array)).

### Data normalization and screening of DEGs

The Affy package (version 1.52.0; [bioconductor.org/packages/release/bioc/html/affy.html](bioconductor.org/packages/release/bioc/html/affy.html)) in R software (version 3.1.3; [www.r-project.org/](www.r-project.org/)) was used for the normalization of the raw CEL data. DEGs in case groups compared with control groups were screened using the limma package (version 3.30.7; [bioconductor.org/packages/release/bioc/html/limma.html](bioconductor.org/packages/release/bioc/html/limma.html)) in R software with the thresholds of P\<0.05 and \|log(fold change)\|\>1.

### Functional enrichment analysis

GO analysis was conducted based on the Database for Annotation, Visualization and Integrated Discovery (DAVID; david.abcc.ncifcrf.gov). Functionally enriched terms with P\<0.05 were considered to be statistically significant. GSEA is a powerful microarray data analysis approach for functional enrichment of gene sets ([@b19-ol-0-0-5779]). It is a computational method that is able to evaluate microarray data at the level of gene sets, which contains predefined biological knowledge from published information about biochemical pathways or coexpression in previous experiments ([@b20-ol-0-0-5779]). GSEA is especially useful when gene expression alterations in a given microarray data set are minimal or moderate. Due to the relatively small sample size in the present study, GSEA was suitable for analyzing the microarray data to obtain the predominant signaling pathways. The number of genes analyzed in the Kyoto Encyclopedia of Genes and Genomes pathway was between 15 and 500, and P\<0.05 was set as the threshold.

The Distant Regulatory Elements of co-regulated genes (DiRE) database ([dire.dcode.org/details.php](dire.dcode.org/details.php)) was used to enrich transcription factors (TFs) in each pathway obtained from GSEA analysis. DiRE is based on the Enhancer Identification method, to determine the chromosomal location and functional characteristics of distant regulatory elements in higher eukaryotic genomes. DiRE was also able to score the association of individual TFs with the biological function shared by the group of input genes.

### PPI network of DEGs

In order to achieve an improved understanding of interactions of DEGs, a PPI network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database ([www.string-db.org](www.string-db.org)), which is primarily known and used to predict protein interactions. PPIs contain direct and indirect connections derived from four sources, including prior knowledge, high-throughput experiments, genomes and coexpression. The visualization of the PPI network was performed using Cytoscape software (version 3.4.0; [www.cytoscape.org](www.cytoscape.org)). The visualized PPI network was able to intuitively present the organization of the interactions of DEGs. Furthermore, the total number of edges connected to a node (defined as the degree) was calculated using Cytoscape.

Results
=======

### Data normalization and screening of DEGs

Microarray data were preprocessed to obtain gene expression profiles. The expression profiling data prior to and following normalization were compared with only limited system deviation existing among samples ([Fig. 1A and B](#f1-ol-0-0-5779){ref-type="fig"}). A total of 6 controls were clustered with 6 samples treated with cediranib from the result of the clustering analysis. A total of 71 DEGs were identified between cediranib-treated samples and controls, including 59 upregulated and 12 downregulated genes ([Table I](#tI-ol-0-0-5779){ref-type="table"}). A hierarchical clustering analysis heat-map is presented in [Fig. 1C](#f1-ol-0-0-5779){ref-type="fig"}, with red representing downregulated DEGs and blue representing upregulated DEGs.

### Functional enrichment analysis

A total of 64 GO terms were identified using DAVID. The 10 most enriched GO terms are presented in [Table II](#tII-ol-0-0-5779){ref-type="table"}. A total of four predominant signaling pathways, including the phenylalanine metabolism pathway, the mitogen-activated protein kinase (MAPK) signaling pathway, the taste transduction pathway and the intestinal immune network for the production of immunoglobulin A were identified using GSEA analysis ([Table III](#tIII-ol-0-0-5779){ref-type="table"}). These four cancer-associated signaling pathways were analyzed using DiRE, and TFs enriched in each pathway were identified. The majority of enriched TFs were components of the MAPK signaling pathway, with 107 identified ([Fig. 2](#f2-ol-0-0-5779){ref-type="fig"}).

### PPI network of DEGs

Identified DEGs of ASPS were imported into the STRING database to construct a PPI network. As a result, a total of 65 nodes were demonstrated to be involved in network construction and 28 interactive genes were established in the network. The visualization of the PPI network is presented in [Fig. 3](#f3-ol-0-0-5779){ref-type="fig"}. Key genes, including Fms-like tyrosine kinase 1 (*FLT1*), kinase insert domain receptor (*KDR*), E-selectin (*SELE*) and PDGFR D (*PDGFD*), possessed degrees of 7, 6, 6 and 3, which were markedly more compared with those of other genes.

Discussion
==========

ASPS is a rare disease that accounts for \~1% of all soft tissue sarcomas ([@b21-ol-0-0-5779]). The clinical course is relatively indolent, and exhibits a marked frequency of metastasis and poor prognosis ([@b22-ol-0-0-5779]). ASPS is typically highly vascular, and research has demonstrated that 18 angiogenesis-associated genes were upregulated ([@b23-ol-0-0-5779]). A number of complementary trials have demonstrated that an anti-angiogenic approach may be the preferred choice in the treatment of ASPS ([@b24-ol-0-0-5779],[@b25-ol-0-0-5779]). Therefore, the anti-angiogenic activity of cediranib and other TKIs, including sunitinib ([@b26-ol-0-0-5779]), make them promising drugs for ASPS. Although cediranib was able to suppress the growth of blood vessels by inhibiting the tyrosine kinase activity, the associated pathways and key genes of the underlying biological processes remain unclear. Therefore, the present study identified four pathways and four key genes associated with the underlying molecular mechanism of ASPS following treatment with cediranib using microarray analysis.

The MAPK signaling pathway containing 107 enriched TFs identified in the present study may be the most important pathway that is affected by cediranib. The MAPK signaling pathway is involved in a variety of cellular functions, including cell proliferation, differentiation and migration ([@b27-ol-0-0-5779]). The MAPK signaling pathway is a downstream signaling cascade that may be activated by mutated RTKs in cancer cells or kinase activity of oncogenes, resulting in tumorigenesis ([@b28-ol-0-0-5779]). Interfering with the mutated tyrosine kinase activity or overexpressing oncogenes, or inhibiting several cancer-associated signaling pathways or cancer angiogenesis, ultimately led to tumor shrinkage and cancer cell death ([@b29-ol-0-0-5779]). The inhibition of the MAPK signaling pathway served a key role in mediating the antitumor effects of TKIs ([@b30-ol-0-0-5779]). The suppression of tumor growth by the TKI cediranib in the treatment of ASPS may occur through the MAPK signaling pathway. The three other signaling pathways identified exhibited fewer enriched TFs and demonstrated limited association with ASPS; further validation of these signaling pathways is required.

Key genes were identified in the PPI network including *FLT1*, *KDR*, *SELE* and *PDGFD*. *FLT1* and *KDR* are tyrosine kinases also known as VEGFR-1 and VEGFR-2, and are associated with angiogenesis and vascular proliferation. Angiogenesis is associated with various physiological and pathophysiological processes. The growth of tumors requires abundant blood vessels to provide adequate oxygen. Overexpression of vascular endothelial growth factor (VEGF) may predict cancer recurrence, metastasis and decreased survival ([@b31-ol-0-0-5779]). However, vascular proliferation and angiogenesis are regulated by VEGF specifically acting on the vascular endothelium via the endothelial cell receptors *FLT1* and *KDR* ([@b32-ol-0-0-5779]). Keyt *et al* ([@b33-ol-0-0-5779]) reported that *FLT1* and *KDR* may serve to dimerize RTKs, resulting in endothelial mitogenesis, proliferation, and initiation of angiogenesis and vasculogenesis. Another study demonstrated that overexpression of *FLT1* and *KDR* were associated with local disease recurrence and metastases of colorectal tumor ([@b34-ol-0-0-5779]). High expression of phosphorylated *KDR* was associated with increased tumor diameter and poor histological differentiation ([@b35-ol-0-0-5779]). Therefore, cediranib, as a VEGF TKI, was able to block the formation of new blood vessels and exhibit anti-tumor activity in therapy of ASPS ([@b16-ol-0-0-5779]). *In vitro*, cediranib inhibited VEGF-stimulated proliferation and *KDR* phosphorylation, and inhibits *FLT1*-associated kinase ([@b36-ol-0-0-5779]). *In vivo*, cediranib exhibited broad-spectrum activity in human tumor models to suppress tubule sprouting and inhibit VEGF-induced angiogenesis ([@b37-ol-0-0-5779],[@b38-ol-0-0-5779]).

Cediranib, an inhibitor of *FLT1* and *KDR*, has also been demonstrated to be able suppress platelet-derived growth factor (PDGF) ([@b39-ol-0-0-5779]). This is because the PDGF receptors (PDGFRs) are structurally and functionally similar to the VEGFRs ([@b33-ol-0-0-5779]). *PDGFD* belongs to the PDGF family and is a growth factor that is able to regulate a number of cellular processes, including cell proliferation, transformation, invasion and angiogenesis ([@b40-ol-0-0-5779]). A number of TKIs have been used for targeted anti-cancer therapeutic agents to block PDGFRs. For instance, imatinib (STI-571) effectively inhibited PDGFR, and thus cell growth and potential invasion in human breast cancer cell lines ([@b41-ol-0-0-5779]). Cediranib reduced intraosseous growth of prostate tumors and exhibited a marked inhibition of tumor-associated bone response in patients with overexpression of *PDGFD* ([@b42-ol-0-0-5779]). Furthermore, cediranib exhibited marked potency to inhibit the PDGFR-associated kinases PDGFR-α and PDGFR-β, similar to VEGFR tyrosine kinases ([@b43-ol-0-0-5779]). These results suggested that inactivation of *PDGFD* or PDGFR is a novel approach to cancer therapy.

Another high degree gene obtained from the PPI network was *SELE*, primarily because it exhibited affinity with high-frequency ASPS metastasis. In humans, *SELE* encodes E-selectin, a member of the selectin family of cell adhesion molecules ([@b44-ol-0-0-5779]), and is expressed only on endothelial cells and activated by cytokines ([@b45-ol-0-0-5779]). E-selectin is not stored in cells, and has to be transcribed, translated and transported to the cell surface. The functions of E-selectin are primarily associated with inflammation and cancer metastasis. During inflammation, E-selectin serves an important function in recruiting leukocytes to the site of injury and damaged cells induces the overexpression of E-selectin on endothelial cells of nearby blood vessels ([@b46-ol-0-0-5779]). As the inflammatory response progresses, chemokines released by injured tissue enter the blood vessels and begin translocating to the tissue ([@b46-ol-0-0-5779]). Furthermore, E-selectin mediates the adhesion of tumor cells to endothelial cells, by binding to E-selectin ligands on the tumor cells, and E-selectin ligands also serve a role in cancer metastasis ([@b44-ol-0-0-5779]). Tumor cells are able to infiltrate the inflammatory system by interacting with selectins. Therefore, this interaction leads to metastatic dissemination of cancer.

GSEA, used in the present study to enrich signaling pathways, has many advantages compared with traditional methods ([@b47-ol-0-0-5779],[@b48-ol-0-0-5779]). GSEA makes it simple to identify pathways and processes for annotation of a large-scale experiment ([@b49-ol-0-0-5779]). Other tools used pathway or ontological information to analyze gene expression ([@b50-ol-0-0-5779],[@b51-ol-0-0-5779]), whereas, with GSEA, rather than focusing on identifying individual genes between two samples and high scoring genes, researchers are able to focus on more interpretable and more reproducible gene sets. Other features, including promoting the signal-to-noise ratio, detecting minor changes in individual genes, and defining gene subsets, either sensitive or robust, lead to GSEA having wider application ([@b20-ol-0-0-5779]).

The MAPK signaling pathway and four key genes obtained using GSEA were demonstrated to be associated with the pathogenesis of ASPS. However, a limitation of the present study is that the sample size is limited. This is associated with the low incidence of ASPS. Therefore, these data require further experimental validation. In future studies, the key genes associated with ASPS require investigation using a preclinical model to reveal the underlying molecular mechanisms of cediranib in ASPS treatment and provide novel insight into cediranib as a therapy for ASPS.
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![Microarray data normalization and heat-map of DEGs. Microarray data, (A) prior to normalization and (B) following normalization. Red represents pre-treatment with cediranib and blue represents post-treatment with cediranib, for between 3 and 5 days. (C) Hierarchical clustering analysis heat-map of DEGs. Red represents downregulated genes and blue represents upregulated genes. DEG, differentially expressed gene.](ol-13-04-2623-g00){#f1-ol-0-0-5779}

![Enrichment scores of the MAPK signaling pathway. 'Case' represents the case groups. 'Control' represents the control groups. KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase.](ol-13-04-2623-g01){#f2-ol-0-0-5779}

![Protein-protein interaction network of DEGs. Spheres represent DEGs and lines represent direct interactions between DEGs. DEG, differentially expressed gene.](ol-13-04-2623-g02){#f3-ol-0-0-5779}

###### 

A total of 71 differentially expressed genes that were identified between pre-treated and post-treated with cediranib for between 3 and 5 days.

  Gene           P-value    Log(fold change)
  -------------- ---------- ------------------
  KCNE3          0.000005   −1.919640
  ANGPT2         0.000008   −2.396400
  TM4SF18        0.000011   −1.561610
  CALCRL         0.000026   −1.376910
  NETO2          0.000032   −1.546550
  GPR4           0.000052   −1.008890
  ESM1           0.000076   −3.129660
  TNFRSF4        0.000082   −1.148190
  ITGA8          0.000095   −1.693490
  FLT1           0.000119   −2.289080
  SERPINI1       0.000134   −1.854420
  ZEB1           0.000175   −1.179100
  SEMA3F         0.000211   −1.178100
  KDR            0.000538   −1.245470
  GABRD          0.000648   −1.209740
  KCNJ2          0.000764   −1.785310
  ADAMTS5        0.000787   −1.325420
  LOC653602      0.000800   −1.609370
  FAM19A5        0.001229   −1.278160
  ACKR3          0.001235   −1.718300
  FOLH1          0.001352   −2.054950
  PLXNA2         0.001447   −1.165320
  PLVAP          0.001538   −1.436030
  ADAMTS9        0.001662   −1.174250
  EFNB2          0.002143   −1.194150
  PRDM1          0.002486   −1.176870
  RBP7           0.002693   −1.036200
  CCL2           0.002933   1.738888
  HECW2          0.003132   −1.301010
  CXorf36        0.003219   −1.168170
  FOLH1B         0.003407   −1.698340
  SOX11          0.003442   −1.681560
  SELE           0.003804   1.598531
  BNIP3          0.004939   1.310759
  CDH13          0.004995   −1.376530
  LBH            0.005046   −1.112670
  RGS5           0.005448   −1.598050
  TRIL           0.006434   −1.290740
  MECOM          0.006666   −1.006220
  C3orf70        0.006700   −1.168890
  TAGLN          0.008038   1.182453
  P2RY8          0.008253   −1.000790
  PNKD           0.009432   1.002066
  FAM84A         0.009696   −1.104130
  BTNL9          0.010359   −1.134410
  APOLD1         0.010814   −1.208060
  NPNT           0.010933   −1.444800
  IL1RN          0.011180   1.857269
  SLC16A14       0.011959   −1.107210
  EDNRB          0.014824   −1.235820
  CA4            0.021125   −1.112460
  PTP4A3         0.022276   −1.042590
  PLCL1          0.023654   −1.168560
  STC1           0.024547   −1.287580
  CYP26B1        0.024733   1.383835
  MIR210HG       0.025097   1.387346
  GUCY1A2        0.026047   −1.060530
  SPP1           0.026251   1.563289
  COL21A1        0.027842   −1.098360
  PDGFRA         0.029188   1.513710
  S1PR3          0.030017   −1.043710
  RGCC           0.031406   −1.129620
  AK4            0.031932   1.445851
  CA2            0.032294   −1.361530
  PDGFD          0.032935   −1.075380
  P2RY14         0.036130   −1.002250
  MFSD6          0.037175   −1.206520
  LOC100288985   0.043962   −1.748150
  HEY1           0.044615   −1.228280
  CD200          0.045409   −1.060250
  FCGR2B         0.046718   1.896813

###### 

Most enriched GO terms for differentially expressed genes.

  Category   GO ID        GO name                                                Number of genes   P-value
  ---------- ------------ ------------------------------------------------------ ----------------- -------------
  CC         GO:0044421   Extracellular region part                              14                7.23×10^−5^
  BP         GO:0016477   Cell migration                                           8               8.32×10^−5^
  CC         GO:0005576   Extracellular region                                   20                1.50×10^−4^
  BP         GO:0048870   Cell motility                                            8               1.61×10^−4^
  BP         GO:0051674   Localization of cell                                     8               1.61×10^−4^
  BP         GO:0001944   Vasculature development                                  7               3.83×10^−4^
  MF         GO:0005021   Vascular endothelial growth factor receptor activity     3               4.01×10^−4^
  CC         GO:0005887   Integral to plasma membrane                            14                6.00×10^−4^
  BP         GO:0042127   Regulation of cell proliferation                       11                7.13×10^−4^
  CC         GO:0031226   Intrinsic to plasma membrane                           14                7.43×10^−4^

GO, gene ontology; ID, identifier; CC, cellular component; BP, biological process; MF, molecular function.

###### 

Predominant signaling pathways identified using Gene Set Enrichment Analysis.

  Pathway name                                        ES     NES    Nominal P-value
  --------------------------------------------------- ------ ------ -----------------
  KEGG_PHENYLALANINE_METABOLISM                       0.78   1.22   0.002
  KEGG_MAPK_SIGNALING_PATHWAY                         0.28   1.31   0.012
  KEGG_TASTE_TRANSDUCTION                             0.39   1.46   0.028
  KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION   0.53   1.5    0.038

ES, enrichment score; NES, normalized enrichment score; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; IgA, immunoglobulin A.
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